TITLE

Phase2 study of bevacizumab with carboplatin-paclitaxel for non-small cell lung cancer with malignant pleural effusion

AUTHOR(S)
Tamiya, Motohiro; Tamiya, Akihiro; Yamadori, Tadahiro; Nakao, Keiko; Asami, Kazuhiro; Yasue, Tomomi; Otsuka, Tomoyuki; Shiroyama, Takayuki; Morishita, Naoko; Suzuki, Hidekazu; Okamoto, Norio; Okishio, Kyoichi; Kawaguchi, Tomoya; Atagi, Shinji; Kawase, Ichiro; Hirashima, Tomonori
PUB. DATE
September 2013
SOURCE
Medical Oncology;Sep2013, Vol. 30 Issue 3, p1
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
No abstract available.
ACCESSION #
89980933

 

Related Articles

  • Chemotherapy and Radiotherapy.  // Current Medical Literature: Lung Cancer;2011, Vol. 4 Issue 4, p123 

    A review of articles on lung chemotherapy and radiotherapy in 2011 is presented including "Increased Risk of Serious Hemorrhage With Bevacizumab in Cancer Patients: A Meta-Analysis," by A. Sher et al., which appeared in "Oncology," "Quality of Surgical Resection for Nonsmall Cell Lung Cancer in...

  • Stage IV lung cancer: Is cure possible? Thippeswamy, Ravi; Noronha, Vanita; Krishna, Vamshi; Joshi, Amit; Bal, Munita Meenu; Purandare, Nilendu; Rangarajan, V.; Pramesh, C. S.; Jiwnani, Sabita; Kumar, Prabhash // Indian Journal of Medical & Paediatric Oncology;Apr-Jun2013, Vol. 34 Issue 2, p121 

    Reporting a case, 53 years old male with stage IV Nonsamall cell lung cancer in view of cytologically proven malignant pleural effusion. Usually the management of stage IV lung cancer is with palliative intent where the patient receives palliative chemotherapy along with palliative radiotherapy...

  • Erlotinib.  // Reactions Weekly;10/23/2010, Issue 1324, p18 

    The article describes the cases of three patients who developed symptoms, including folliculitis, paronychia, fatigue and hair changes while receiving erlotinib for non-small cell lung cancer. The patients were a 61-year-old woman who was found to have right-lung adenocarcinoma with two brain...

  • Effect of IL-6 Elevation in Malignant Pleural Effusion on Hyperfibrinogenemia in Lung Cancer Patients. Yamaguchi, Toshihiko; Kimura, Hiromi; Yokota, Soichiro; Yamamoto, Yuko; Hashimoto, Taikichi; Nakagawa, Masaru; Ito, Masami; Ogura, Takeshi // Japanese Journal of Clinical Oncology;Feb2000, Vol. 30 Issue 2 

    Investigates the effect of interleukin-6 (IL-6) elevation in malignant pleural effusion on hyperfibrinogenemia in lung cancer patients. Measurements of IL-6 and tumor necrosis factor-alpha in serum and pleural effusion; Immunohistochemical detection of IL-6 in pleural cells; Systemic leakage of...

  • Nivolumab: Pseudoprogression in the form of pleural and pericardial effusions: case report.  // Reactions Weekly;2/8/2020, Vol. 1790 Issue 1, p174 

    A 73-year-old man developed pseudoprogression in the form of pleural and pericardial effusions during treatment with nivolumab for non-small cell lung cancer. He had developed pseudoprogression in the form of pleural and pericardial effusions secondary to nivolumab [ I time to reaction onset not...

  • Expression of Matrix Metalloproteinase-9 in Pleural Effusions of Tuberculosis and Lung Cancer. Kwang Joo Park; Sung Chul Hwang; Seung Soo Sheen; Yoon Jung Oh; Jae Ho Han; Kyi Beum Lee // Respiration;Mar/Apr2005, Vol. 72 Issue 2, p166 

    Background: Matrix metalloproteinase (MMP)-9 has been implicated in the development of pleural effusions. Objectives: The aim of this study was to assess the expression of MMP-9 in pleural effusions of tuberculosis, lung cancer and transudates. Methods: Ninety-one patients (37 tuberculous...

  • Bevacizumab.  // Reactions Weekly;Apr2015, Vol. 1547 Issue 1, p59 

    The article presents a case study of a 58-year-old man with unresectable non-small cell carcinoma of the lung, who developed trachea mediastinal parenchymal pleural fistula while on treatment with bevacizumab.

  • Management of a malignant pleural effusion: British Thoracic Society pleural disease guideline 2010. Roberts, Mark E.; Neville, Edmund; Berrisford, Richard G.; Antunes, George; Ali, Nabeel J. // Thorax;AugSupplement, Vol. 65 Issue Supp2, p5 

    The article presents the 2010 British Thoracic Society pleural disease guidelines on the management of a malignant pleural effusion. The presence of malignant cells in pleural fluid and/or parietal pleura indicates disseminated or advanced condition and a reduced life expectancy in cancer...

  • Diagnostic Utility of Pleural Fluid Cell Block versus Pleural Biopsy Collected by Flex-Rigid Pleuroscopy for Malignant Pleural Disease: A Single Center Retrospective Analysis. Miyoshi, Shion; Sasada, Shinji; Izumo, Takehiro; Matsumoto, Yuji; Tsuchida, Takaaki // PLoS ONE;11/23/2016, Vol. 11 Issue 11, p1 

    Background: Some trials recently demonstrated the benefit of targeted treatment for malignant disease; therefore, adequate tissues are needed to detect the targeted gene. Pleural biopsy using flex-rigid pleuroscopy and pleural effusion cell block analysis are both useful for diagnosis of...

  • WIF-1 promoter region hypermethylation as an adjuvant diagnostic marker for non-small cell lung cancer-related malignant pleural effusions. Tsung-Ming Yang; Shaw-Wei Leu; Jhy-Ming Li; Ming-Szu Hung; Chu-Huan Lin; Yu-Ching Lin; Tung-Jung Huang; Ying-Huang Tsai; Cheng-Ta Yang // Journal of Cancer Research & Clinical Oncology;Jul2009, Vol. 135 Issue 7, p919 

    Malignant pleural effusion is an important staging criterion in non-small cell lung cancer (NSCLC). Although cytologic examination remains the major diagnostic tool for NSCLC-related malignant pleural effusion, sometimes other invasive methods maybe required. Aberrant activation of Wnt signaling...

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics